menu
    • menu
    [{"orgOrder":0,"company":"Amphastar Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Succinylcholine Chloride","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Amphastar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amphastar Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Amphastar Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Succinylcholine Chloride","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"INDIA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Succinylcholine Chloride","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Breckenridge Pharmaceutical","sponsor":"Aggrega Pharma","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Agreement","leadProduct":"Succinylcholine Chloride","moa":"ACh receptor","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Breckenridge Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Breckenridge Pharmaceutical \/ Aggrega Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Breckenridge Pharmaceutical \/ Aggrega Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals for Succinocholine

    Menu

    Succinocholine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Breckenridge Pharmaceutical

                            U.S.A
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Aggrega Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Breckenridge Signs Multi-Product Agreement With Aggrega Pharma LLC

                            Details : Breckenridge previously launched Succinylcholine Chloride Injection, USP, 20mg/mL under this agreement, which is now available from Breckenridge as a carton of 25 vials.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Aggrega Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Breckenridge Pharmaceutical

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            CPhI Korea
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr. Reddy's Laboratories Announces the Launch of Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/m...

                            Details : Dr. Reddy's Laboratories has launched Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the USFDA.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 11, 2020

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Nexus Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Nexus Pharmaceuticals Receives FDA Approval for Succinylcholine Chloride Injection, USP

                            Details : Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 29, 2020

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Amphastar Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed

                            Amphastar Pharmaceuticals

                            U.S.A arrow
                            AGGSpend
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Amphastar Pharmaceuticals, Inc. Receives FDA Approval for Succinylcholine Chloride Injection USP, 200 mg/10 mL...

                            Details : The U.S. FDA has approved Abbreviated New Drug Application for Succinylcholine Chloride Injection USP, 200 mg/10 mL Multiple-Dose Vial. Amphastar’s drug product was determined by the FDA to be therapeutically equivalent to Succinylcholine Chloride Inje...

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            September 06, 2020

                            Lead Product(s) : Succinylcholine Chloride

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth